AMIX · Autonomix Medical, Inc. · Insider Trading

Represents restricted stock award vesting one-year from the date of issuance of September 3, 2026.

Represents restricted stock award vesting one-year from the date of issuance of September 3, 2026.

Represents restricted stock award vesting one-year from the date of issuance of September 3, 2026.

Represents restricted stock award vesting one-year from the date of issuance of September 3, 2026.

Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation.

Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation.

Amount represents a revised share amount based on a 1-for-20 reverse stock split from October 25,2024.

Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received three months severance as consideration for the cancellation.

Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received an additional three months severance as consideration for the cancellation.

Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation.

Amount represents a revised share amount based on a 1-for-20 reverse stock split from October 25,2024.

Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received an additional three months severance as consideration for the cancellation.

Amount represents a revised share amount based on a 1-for-20 reverse stock split from October 25, 2024.

Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation.

Issued in connection with the reporting person's employment with the Company.

The option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.

Issued in connection with the reporting person's employment with the Company

The option set forth in this table vests in four annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.

Issued in connection with the reporting person's employment with the Company

The option set forth in this table vests in four annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.

Includes a portion of 1,600,000 warrants to purchase shares of the Company's common stock that was held by Impulse Medical, Inc., in which Mr. Robins owns 19.5% through Portsmouth Therapeutics, Inc., an entity in which Mr. Robins also owns a 33.33% interest. The shares underlying the warrants are subject to a lockup agreement for a period of six months after January 29, 2024 with respect to 12.5% of the shares issued and twelve months after January 29, 2024 for the remainder of the shares.

The ability of the Reporting Person to exercise the warrants is subject to a beneficial ownership limitation initially set at 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of common stock issuable upon exercise of the warrants. This beneficial ownership limitation may be increased or decreased at the election of the holder, provided that the beneficial ownership limitation in no event exceeds 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise of the warrants and any increase shall not be effective until the 61st day after notice of adjustment is provided to the Issuer.

Issued in connection with the reporting person's employment with the Company.

The option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.